Bottom line
Is FACTX a good fund? The bottom line
FACTX is the Class M share class of Fidelity Advisor Health Care Fund, an actively managed health care sector mutual fund from Fidelity.
Annual fees run 1.21% — about $121 a year on every $10,000 invested, more expensive than 70% of health care sector funds we track.
It returned +10.0% over one year, +2.6% a year over five years, +7.6% a year over ten (as of Sep 30, 2026, per its prospectus).
With $3.1 billion in net assets and 154 holdings, its largest position is ELI LILLY and CO (7.7%) and the top 10 make up 41.1% of the portfolio.
What to watch
- 5-year return in the bottom quarter of its category
- 12b-1 marketing fee of 0.5% a year
Updated Nov 19, 2026
What FACTX invests in
Fidelity Advisor Health Care Fund seeks capital appreciation.
Normally investing primarily in common stocks. Normally investing at least 80% of assets in securities of companies principally engaged in the design, manufacture, or sale of products or services used for or in connection with health care or medicine. These companies may include, for example, companies engaged in the research, development, manufacturing, or marketing of products based on biotechnology research; companies engaged in research, development, or production of pharmaceuticals, including veterinary drugs; manufacturers, distributors, and wholesalers of health care equipment, devices, and supplies including drug delivery systems and eye care products; and owners and operators of health care facilities, HMOs, and other managed plans. Fidelity may consider a company to be principally engaged in the designated business activity or activities based on: (i) the level of a company's…
From the fund's prospectus (filed Sep 24, 2026).
FACTX performance
| 1 yr | 5 yr | 10 yr | |
|---|---|---|---|
| FACTX | +10.0% | +2.6% | +7.6% |
| Health Care Sector median | +14.5% | +4.2% | +7.9% |
Source: Fund prospectus, as of Sep 30, 2026
What FACTX costs
On a $10,000 investment, FACTX's 1.21% expense ratio costs about $121 a year. The prospectus estimates $1,765 in total costs over 10 years (assuming 5% annual returns). The median health care sector fund charges 0.96%.
FACTX top 10 holdings
| # | Holding | % of fund |
|---|---|---|
| 1 | ELI LILLY and CO | 7.66% |
| 2 | Danaher Corp | 6.75% |
| 3 | Thermo Fisher Scientific Inc | 6.31% |
| 4 | Unitedhealth Group Inc | 4.17% |
| 5 | JOHNSON and JOHNSON | 3.78% |
| 6 | Abbvie Inc | 3.62% |
| 7 | Fidelity Revere Street Trust | 2.54% |
| 8 | Argenx Se | 2.09% |
| 9 | MERCK and CO INC | 2.09% |
| 10 | West Pharmaceutical Svcs Inc | 2.06% |
Source: SEC Form N-PORT, period ended Jul 31, 2026
The top 10 make up 41.1% of the fund. See all top 25 holdings and asset mix →